CORESTEMCHEMON Inc. 166480
KRX · South Korea · Health Technology
KRW 2,315.00+55.00 (+2.43%)
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Patients with amyotrophic lateral sclerosis (ALS) in South Korea will keep their access to Neuronata-R® (lenzumestrocel) — a stem cell therapy for ALS — after the Ministry of Food and Drug Safety (MFDS) approved its continued use in May 2026, updating the label to reflect data from the completed Phase 3 clinical trial.
CorestemChemon (KOSDAQ: 166480) is entering a critical late-stage phase in the commercialization of its ALS stem cell therapy, Neuronata-R. The company attributes this momentum to advanced domestic regulatory review in Korea, entry into an NSF-supported regenerative medicine ecosystem in the United States, secured commercialization capital, and a sizable open-market share purchase by the CEO.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.